查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1956465

哺乳动物细胞生物製药CDMO服务市场报告：趋势、预测与竞争分析（至2031年）

Mammalian Biologics CDMO Service Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 178 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

由于中小企业和大型企业市场的机会，全球哺乳动物细胞生物製药CDMO服务市场预计将保持强劲增长，并预计从2025年到2031年将以10.1%的复合年增长率增长。主要市场驱动因素包括对生物疗法的需求不断增长、对生产外包解决方案的需求不断增长以及对开发创新生物药物的日益重视。

  • Lucintel 预测，在预测期内，细胞和基因疗法将在所有疗法类别中呈现最高的成长率。
  • 在应用类别中，大型企业市场预计将呈现更高的成长率。
  • 从区域来看，预计亚太地区在预测期内将达到最高的成长率。

哺乳动物细胞生物製药CDMO服务市场的新兴趋势

哺乳动物细胞生物製药CDMO服务市场正经历快速成长，这主要得益于生物技术的进步、个人化医疗需求的不断增长以及对高效生产解决方案的需求。随着製药和生技公司寻求加速药物研发并降低成本，市场也不断演进，涌现出创新技术和策略联盟。这些发展正在改变生技药品的生产、测试和上市方式，为产业相关人员带来新的机会和挑战。对于希望保持竞争力并有效利用新市场动态的公司而言，了解这些新兴趋势至关重要。

  • 一次性技术的应用：这一趋势表明，生物製药生产中一次性生物反应器和设备的使用正在增加。一次性系统具有柔软性、污染风险低、资本投入少等优点，并能快速放大生产规模与製程变更。推动其应用的因素是对经济高效、扩充性且高效的生产流程的需求，尤其是在个人化医疗和小批量生产领域。这种转变提高了营运弹性，缩短了周转时间，使生物製药生产能够更好地适应市场需求。
  • 进阶分析与人工智慧的融合：人工智慧 (AI) 和先进数据分析技术的应用正在变革生物製药生产的流程优化、品管和预测性维护。 AI 驱动的工具能够实现即时监控、异常检测和流程调整，从而提高产量并确保产品品质的稳定性。这种融合降低了生产成本，缩短了研发週期，并加强了合规性。随着数据驱动决策成为常态，企业能够在生物製药研发方面实现更高的效率和创新。
  • 契约製造扩张：我们看到，合约研发生产机构 (CDMO) 大幅提升了其哺乳动物生物製药的生产能力。这一扩张是由市场对生物製药，特别是单株抗体和基因疗法药物日益增长的需求所驱动的。 CDMO 正在投资建造最先进的设施、先进的生物反应器和聘请熟练的专业人员，以满足客户的需求。这一趋势使生技公司能够将生产外包，缩短产品上市时间，并专注于研发，从而创造一个更具协作性和灵活性的产业环境。
  • 关注永续性和绿色製造：环境问题和监管压力正迫使企业在生物製药生产中采用永续的做法。这包括减少能源消耗、废弃物产生和用水量，以及采用环保材料和製程。绿色製造不仅能最大限度地减少对环境的影响，也符合企业社会责任目标和监管标准。这一趋势正在推动产业转型，促进永续生物加工技术的创新，并建立更负责任的供应链。
  • 个人化医疗和细胞疗法的兴起：个人化医疗和细胞疗法市场正经历着爆发式增长，这需要专门的生产过程。合约研发生产机构（CDMO）正在开发灵活且扩充性的平台，以高效生产个人化疗法。这一趋势的驱动力来自基因组学、再生医学和免疫疗法的进步，这些领域需要高度客製化和快速的生产週期。向个人化生物製剂的转变正在改变市场格局，强调敏捷性、创新性和对监管的快速反应，以满足每位患者的独特需求。

总而言之，这些新兴趋势正在透过提高生产效率、增加创新和注重永续性来重塑哺乳动物细胞生物製药 CDMO 服务市场，从而支持更短的开发週期、降低成本和个人化医疗的发展，最终形成一个更具活力和响应能力的行业格局。

哺乳动物细胞生物製药CDMO服务市场的最新趋势

由于生技药品需求不断增长、生物技术研究取得进展以及对专业化生产服务的需求，哺乳动物细胞生物製药CDMO服务市场正经历快速成长。随着製药和生物技术公司寻求高效、扩充性且合规的生技药品生产解决方案，市场正透过创新技术和策略联盟不断发展。这些发展正在重塑市场格局，从而提高产品品质、加快产品上市速度并扩大全球覆盖范围。以下关键发展突显了这个充满活力的市场的当前方向和未来潜力。

  • 扩大产能和基础设施：为满足日益增长的哺乳动物源生物製药需求，领先的合约研发生产机构（CDMO）正投资建设新设施併升级现有设施。这些扩建将提高生产能力、缩短前置作业时间并增强服务，从而加速向全球患者提供生物製药疗法。
  • 采用先进的生物製程技术：连续製程、一次性系统和自动化整合正在变革生物製剂的生产。这些技术提高了效率、降低了成本并改善了产品的一致性，从而为企业在市场竞争中带来优势。
  • 策略联盟与伙伴关係：各公司正与生物技术公司、学术机构和技术提供者结盟，以获得创新平台并扩展其服务组合，从而缩短开发时间并促进生物製药製造领域的创新。
  • 注重合规性和品质标准：加强对全球法规结构的遵守，确保产品的安全性和有效性。合约研发生产机构（CDMO）实施严格的品管体系，以建立客户信任并促进顺利的核准流程。
  • 对客製化和专业服务的需求不断增长：市场对客製化生物製药生产解决方案的需求不断增长，包括细胞株开发、製程优化和填充包装服务，这反映了对个人化疗法和复杂生物製药的需求。

总之，这些发展正透过扩大产能、提升技术整合、促进策略合作、确保合规性以及满足个人化医疗需求，对哺乳动物细胞生物製药CDMO服务市场产生重大影响。这些措施共同推动市场成长，提升服务质量，并实现生技药品更快、更有效率的研发和生产。

目录

第一章执行摘要

第二章 市场概览

  • 背景和分类
  • 供应链

第三章：市场趋势与预测分析

  • 宏观经济趋势与预测
  • 产业驱动因素与挑战
  • PESTLE分析
  • 专利分析
  • 法规环境

4. 全球哺乳动物生技药品CDMO服务市场（按类型划分）

  • 吸引力分析：按类型
  • 细胞和基因治疗
  • 抗体
  • 疫苗
  • 其他的

5. 全球哺乳动物细胞生物製药CDMO服务市场（依应用领域划分）

  • 吸引力分析：依目的
  • 小型企业
  • 大公司

第六章 区域分析

7. 北美哺乳动物细胞生物製药CDMO服务市场

  • 北美哺乳动物细胞生物製药CDMO服务市场（按类型划分）
  • 北美哺乳动物细胞生物製药CDMO服务市场（按应用领域划分）
  • 美国哺乳动物细胞生物製药CDMO服务市场
  • 加拿大哺乳动物细胞生物製药CDMO服务市场
  • 墨西哥哺乳动物细胞生物製药CDMO服务市场

8. 欧洲哺乳动物细胞生物製药CDMO服务市场

  • 欧洲哺乳动物细胞生物製药CDMO服务市场（按类型划分）
  • 欧洲哺乳动物细胞生物製药CDMO服务市场依应用领域划分
  • 德国哺乳动物细胞生物製药CDMO服务市场
  • 法国哺乳动物细胞生物製药CDMO服务市场
  • 义大利哺乳动物细胞生物製药CDMO服务市场
  • 西班牙哺乳动物细胞生物製药CDMO服务市场
  • 英国哺乳动物细胞生物製药CDMO服务市场

9. 亚太地区哺乳动物细胞生物製药CDMO服务市场

  • 亚太地区哺乳动物细胞生物製药CDMO服务市场（按类型划分）
  • 亚太地区哺乳动物细胞生物製药CDMO服务市场（依应用划分）
  • 中国哺乳动物细胞生物製药CDMO服务市场
  • 印度哺乳动物细胞生物製药CDMO服务市场
  • 日本哺乳动物细胞生物製药CDMO服务市场
  • 韩国哺乳动物细胞生物製药CDMO服务市场
  • 印尼哺乳动物细胞生物製药CDMO服务市场

10. 其余哺乳动物生技药品CDMO服务市场

  • 世界其他地区哺乳动物细胞生物製药CDMO服务市场（按类型划分）
  • 世界其他地区哺乳动物细胞生物製药CDMO服务市场（按应用领域划分）
  • 中东哺乳动物细胞生物製药CDMO服务市场
  • 南美洲哺乳动物细胞生物製药CDMO服务市场
  • 非洲哺乳动物源性生技药品CDMO服务市场

第十一章 竞争分析

  • 产品系列分析
  • 业务整合
  • 波特五力分析
  • 市占率分析

第十二章：机会与策略分析

  • 价值链分析
  • 成长机会分析
  • 全球哺乳动物细胞生物製药CDMO服务市场新兴趋势
  • 战略分析

第十三章 价值链主要企业的公司概况

  • Competitive Analysis Overview
  • Lonza
  • Catalent
  • Samsung Biologics
  • FUJIFILM Diosynth Biotechnologies
  • Boehringer Ingelheim
  • WuXi AppTech
  • Recipharm
  • Thermo Fisher Scientific
  • AGC Biologics
  • Rentschler Biopharma

第十四章附录

简介目录

The future of the global mammalian biologics CDMO service market looks promising with opportunities in the SMB and large company markets. The global mammalian biologics CDMO service market is expected to grow with a CAGR of 10.1% from 2025 to 2031. The major drivers for this market are the increasing demand for biologic therapies, the rising need for outsourced manufacturing solutions, and the growing focus on innovative biologic drug development.

  • Lucintel forecasts that, within the type category, cell & gene therapy is expected to witness the highest growth over the forecast period.
  • Within the application category, large company is expected to witness higher growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Mammalian Biologics CDMO Service Market

The mammalian biologics CDMO service market is experiencing rapid growth driven by advancements in biotechnology, increasing demand for personalized medicine, and the need for efficient manufacturing solutions. As pharmaceutical and biotech companies seek to accelerate drug development and reduce costs, the market is evolving with innovative technologies and strategic collaborations. These developments are transforming how biologics are produced, tested, and brought to market, creating new opportunities and challenges for industry stakeholders. Understanding these emerging trends is crucial for companies aiming to stay competitive and leverage new market dynamics effectively.

  • Adoption of Single-Use Technologies: This trend involves the increasing use of disposable bioreactors and equipment in biologics manufacturing. Single-use systems offer flexibility, reduced contamination risk, and lower capital investment, enabling faster scale-up and process changes. Their adoption is driven by the need for cost-effective, scalable, and efficient manufacturing processes, especially for personalized medicines and small-batch productions. This shift enhances operational agility and reduces turnaround times, making biologics production more adaptable to market demands.
  • Integration of Advanced Analytics and AI: The use of artificial intelligence and advanced data analytics is transforming process optimization, quality control, and predictive maintenance in biologics manufacturing. AI-driven tools enable real-time monitoring, anomaly detection, and process adjustments, leading to higher yields and consistent product quality. This integration reduces manufacturing costs, shortens development timelines, and enhances regulatory compliance. As data-driven decision-making becomes standard, companies can achieve greater efficiency and innovation in biologics development.
  • Expansion of Contract Manufacturing Capabilities: There is a significant increase in the number of CDMOs expanding their mammalian biologics manufacturing capacities. This expansion is driven by rising demand for biologics, especially monoclonal antibodies and gene therapies. CDMOs are investing in state-of-the-art facilities, advanced bioreactors, and a skilled workforce to meet client needs. This trend allows biotech firms to outsource manufacturing, reduce time-to-market, and focus on R&D, fostering a more collaborative and flexible industry environment.
  • Focus on Sustainability and Green Manufacturing: Environmental concerns and regulatory pressures are prompting companies to adopt sustainable practices in biologics production. This includes reducing energy consumption, waste generation, and water usage, as well as implementing eco-friendly materials and processes. Green manufacturing not only minimizes environmental impact but also aligns with corporate social responsibility goals and regulatory standards. This trend is reshaping the industry by encouraging innovation in sustainable bioprocessing technologies and fostering a more responsible supply chain.
  • Rise of Personalized and Cell-Based Therapies: The market is witnessing a surge in personalized medicine and cell-based therapies, requiring specialized manufacturing processes. CDMOs are developing flexible, scalable platforms to produce individualized treatments efficiently. This trend is driven by advancements in genomics, regenerative medicine, and immunotherapy, demanding high customization and rapid production cycles. The shift towards personalized biologics is transforming the market landscape, emphasizing agility, innovation, and regulatory adaptation to meet the unique needs of each patient.

In summary, these emerging trends are reshaping the mammalian biologics CDMO service market by enhancing manufacturing efficiency, fostering innovation, and emphasizing sustainability. They are enabling faster development cycles, reducing costs, and supporting the growth of personalized medicine, ultimately leading to a more dynamic and responsive industry landscape.

Recent Developments in the Mammalian Biologics CDMO Service Market

The mammalian biologics CDMO service market is experiencing rapid growth driven by increasing demand for biologics, advancements in biotechnological research, and the need for specialized manufacturing services. As pharmaceutical and biotech companies seek efficient, scalable, and compliant solutions for biologic production, the market is evolving with innovative technologies and strategic collaborations. These developments are shaping the landscape, enhancing product quality, reducing time-to-market, and expanding global reach. The following key developments highlight the current trajectory and future potential of this dynamic market.

  • Expansion of Capacity and Infrastructure: Major CDMOs are investing in new facilities and upgrading existing ones to meet rising demand for mammalian biologics. This expansion improves manufacturing capacity, reduces lead times, and enhances service offerings, enabling faster delivery of biologic therapies to patients worldwide.
  • Adoption of Advanced Bioprocessing Technologies: Integration of continuous processing, single-use systems, and automation is transforming biologics manufacturing. These technologies increase efficiency, reduce costs, and improve product consistency, giving companies a competitive edge in the market.
  • Strategic Collaborations and Partnerships: Companies are forming alliances with biotech firms, academic institutions, and technology providers to access innovative platforms and expand their service portfolios. Such collaborations accelerate development timelines and foster innovation in biologic production.
  • Focus on Regulatory Compliance and Quality Standards: Enhanced emphasis on compliance with global regulatory frameworks ensures product safety and efficacy. CDMOs are adopting rigorous quality management systems, which build trust with clients and facilitate smoother approval processes.
  • Growing Demand for Custom and Specialized Services: The market is witnessing increased demand for tailored biologic manufacturing solutions, including cell line development, process optimization, and fill-finish services. This trend reflects the need for personalized therapies and complex biologic products.

In summary, these developments are significantly impacting the mammalian biologics CDMO service market by increasing capacity, improving technological integration, fostering strategic collaborations, ensuring regulatory compliance, and catering to personalized medicine needs. Collectively, they are driving market growth, enhancing service quality, and enabling faster, more efficient biologic drug development and manufacturing.

Strategic Growth Opportunities in the Mammalian Biologics CDMO Service Market

The mammalian biologics CDMO service market is experiencing rapid expansion driven by increasing demand for biologics across various industries such as pharmaceuticals, biotechnology, and research institutions. Advances in biotechnological research, rising prevalence of chronic diseases, and the need for specialized manufacturing services are fueling this growth. Companies are focusing on innovative solutions to meet stringent regulatory standards and reduce time-to-market for new biologics. As the market evolves, key applications are presenting significant growth opportunities that can shape the future landscape of biologics development and manufacturing.

  • Enhancing Productivity and Stability: The development of high-yield, stable cell lines is crucial for efficient biologics production, leading to faster development cycles and reduced costs, thereby attracting more clients seeking reliable manufacturing solutions.
  • Improving Efficiency and Scalability: Focus on refining bioprocesses to ensure higher yields, lower production costs, and scalable solutions, which are vital for meeting increasing global demand for biologics.
  • Accelerating Drug Approval Processes: Providing high-quality, compliant clinical trial materials helps pharmaceutical companies expedite clinical phases, reducing time-to-market and increasing market competitiveness.
  • Ensuring Regulatory Compliance and Large-scale Production: Scaling up production while maintaining quality standards is essential for market supply, enabling companies to meet global demand and expand their market share.
  • Ensuring Product Safety and Efficacy: Advanced testing and validation services ensure biologics meet regulatory standards, fostering trust and facilitating smoother approval processes across markets.

In summary, these growth opportunities are significantly impacting the mammalian biologics CDMO service market by driving innovation, improving efficiency, and ensuring regulatory compliance. This, in turn, accelerates the development and commercialization of biologics, fostering market expansion and increased competitiveness.

Mammalian Biologics CDMO Service Market Driver and Challenges

The mammalian biologics CDMO service market is influenced by a complex interplay of technological advancements, economic factors, and regulatory frameworks. As the biopharmaceutical industry continues to evolve, the demand for specialized contract development and manufacturing services for mammalian biologics grows. Innovations in cell line development, process optimization, and scalable manufacturing technologies are key drivers. Simultaneously, economic considerations such as rising R&D investments and the need for cost-effective production methods shape market dynamics. Regulatory compliance and quality standards also significantly impact market growth, ensuring safety and efficacy. Navigating these multifaceted factors is crucial for stakeholders aiming to capitalize on emerging opportunities while addressing inherent challenges.

The factors responsible for driving the mammalian biologics CDMO service market include:

  • Technological Innovation: The rapid development of advanced bioprocessing technologies, such as high-yield cell line development and continuous manufacturing, enhances production efficiency and product quality. These innovations enable CDMOs to meet the increasing demand for complex biologics, reduce time-to-market, and improve scalability. As biopharmaceutical companies seek more reliable and cost-effective manufacturing solutions, technological progress becomes a pivotal driver, fostering market expansion and competitiveness.
  • Rising Biopharmaceutical R&D Investment: The global increase in R&D expenditure by pharmaceutical and biotech companies fuels demand for specialized CDMO services. As companies focus on developing novel biologics, they require expert manufacturing partners to handle complex processes. This investment trend supports the growth of the mammalian biologics CDMO market by expanding capacity, encouraging innovation, and enabling faster development cycles, ultimately accelerating the availability of new therapies.
  • Growing Prevalence of Chronic Diseases: The rising incidence of chronic conditions such as cancer, autoimmune disorders, and infectious diseases drives demand for biologic therapies. These therapies often require sophisticated manufacturing processes provided by mammalian cell-based systems. The increasing need for personalized and targeted treatments further amplifies the demand for high-quality biologics, positioning CDMOs as essential partners in delivering these advanced medicines.
  • Regulatory Support and Quality Standards: Stringent regulatory frameworks and quality assurance protocols ensure the safety and efficacy of biologics. While compliance can be challenging, it also creates opportunities for specialized CDMOs to offer validated, compliant manufacturing solutions. The evolving regulatory landscape encourages innovation in quality management and process validation, fostering trust and facilitating market entry for new biologics.
  • Strategic Collaborations and Partnerships: Collaborations between biopharmaceutical companies and CDMOs enable resource sharing, risk mitigation, and access to advanced technologies. These strategic alliances accelerate development timelines and expand manufacturing capacity. As the market becomes more competitive, such partnerships are vital for innovation, cost reduction, and market penetration, thereby driving overall industry growth.

The challenges facing this mammalian biologics CDMO service market include:

  • High Capital and Operational Costs: Establishing and maintaining mammalian cell culture facilities require significant investment in infrastructure, equipment, and skilled personnel. These costs can be prohibitive for smaller firms and may limit market entry. Additionally, operational expenses related to raw materials, quality control, and regulatory compliance add to financial burdens, potentially impacting profitability and scalability.
  • Complex Regulatory Environment: Navigating diverse and evolving regulatory requirements across different regions poses a significant challenge. Ensuring compliance with Good Manufacturing Practices (GMP), validation protocols, and safety standards demands substantial resources and expertise. Regulatory delays or non-compliance can hinder product approval, increase costs, and affect market competitiveness.
  • Technological Uncertainties and Risks: Despite advancements, bioprocessing technologies are inherently complex and susceptible to variability. Risks such as process failures, contamination, and batch inconsistencies can lead to delays and increased costs. Keeping pace with rapid technological changes also requires continuous investment in innovation and staff training, which can strain resources and impact operational stability.

In summary, the mammalian biologics CDMO service market is shaped by significant technological innovations, increasing R&D investments, and rising disease prevalence, all of which foster growth. However, high costs, regulatory complexities, and technological risks pose substantial hurdles. The interplay of these drivers and challenges determines the market's trajectory, requiring stakeholders to strategically navigate evolving landscapes. Successful adaptation to these factors will be essential for sustained growth and competitive advantage in this dynamic industry.

List of Mammalian Biologics CDMO Service Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies mammalian biologics CDMO service companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the mammalian biologics CDMO service companies profiled in this report include-

  • Lonza
  • Catalent
  • Samsung Biologics
  • FUJIFILM Diosynth Biotechnologies
  • Boehringer Ingelheim
  • WuXi AppTech
  • Recipharm
  • Thermo Fisher Scientific
  • AGC Biologics
  • Rentschler Biopharma

Mammalian Biologics CDMO Service Market by Segment

The study includes a forecast for the global mammalian biologics CDMO service market by type, application, and region.

Mammalian Biologics CDMO Service Market by Type [Value from 2019 to 2031]:

  • Cell & Gene Therapies
  • Antibodies
  • Vaccines
  • Others

Mammalian Biologics CDMO Service Market by Application [Value from 2019 to 2031]:

  • SMBs
  • Large Companies

Mammalian Biologics CDMO Service Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Mammalian Biologics CDMO Service Market

The mammalian biologics CDMO service market is experiencing rapid growth driven by increasing demand for biologics, advancements in biotechnologies, and expanding pharmaceutical pipelines worldwide. As companies seek specialized manufacturing solutions, regions are innovating to meet regulatory standards and improve production efficiency. The United States, China, Germany, India, and Japan are key players, each contributing unique developments that shape the global landscape. These countries are investing heavily in research, infrastructure, and strategic collaborations to enhance their capabilities and competitiveness in this evolving market.

  • United States: The US market is witnessing significant investments in advanced bioprocessing technologies and automation. Leading firms are expanding their facilities to accommodate complex biologics, with a focus on personalized medicine and cell therapy manufacturing. Regulatory agencies are streamlining approval processes, fostering innovation, and faster market entry. The US also sees increased collaborations between biotech startups and CDMOs to accelerate product development.
  • China: China is rapidly emerging as a major hub for biologics manufacturing, with government initiatives supporting biotech innovation. The country is expanding its CDMO infrastructure, focusing on cost-effective production and quality improvements. Chinese firms are investing in advanced bioreactor systems and quality control measures to meet international standards. Strategic partnerships with Western companies are also on the rise, boosting technological transfer and expertise.
  • Germany: Germany remains a leader in biopharmaceutical manufacturing within Europe, emphasizing high-quality standards and regulatory compliance. The country is advancing in the development of single-use bioreactors and continuous manufacturing processes. German CDMOs are increasingly adopting digital solutions for process optimization and data management. The focus is on sustainable practices and reducing environmental impact in biologics production.
  • India: India's biologics CDMO sector is expanding rapidly, driven by a large pool of skilled scientists and cost advantages. The country is investing in state-of-the-art manufacturing facilities and quality assurance systems. Indian companies are focusing on biosimilars and generic biologics, catering to both domestic and international markets. The government's supportive policies are encouraging foreign direct investment and technology transfer.
  • Japan: Japan is strengthening its biologics manufacturing capabilities through innovation in cell culture technologies and bioprocessing. The country is emphasizing quality and safety, aligning with stringent regulatory standards. Japanese CDMOs are adopting automation and AI-driven analytics to improve efficiency. There is also a focus on developing therapies for aging-related diseases, with collaborations between academia and industry fostering new advancements.

Features of the Global Mammalian Biologics CDMO Service Market

  • Market Size Estimates: Mammalian biologics CDMO service market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Mammalian biologics CDMO service market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Mammalian biologics CDMO service market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the mammalian biologics CDMO service market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the mammalian biologics CDMO service market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the mammalian biologics CDMO service market by type (cell & gene therapies, antibodies, vaccines, and others), application (SMBs and large companies), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Mammalian Biologics CDMO Service Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Cell & Gene Therapies : Trends and Forecast (2019-2031)
  • 4.4 Antibodies : Trends and Forecast (2019-2031)
  • 4.5 Vaccines : Trends and Forecast (2019-2031)
  • 4.6 Others : Trends and Forecast (2019-2031)

5. Global Mammalian Biologics CDMO Service Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 SMBs : Trends and Forecast (2019-2031)
  • 5.4 Large Companies : Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Mammalian Biologics CDMO Service Market by Region

7. North American Mammalian Biologics CDMO Service Market

  • 7.1 Overview
  • 7.2 North American Mammalian Biologics CDMO Service Market by Type
  • 7.3 North American Mammalian Biologics CDMO Service Market by Application
  • 7.4 The United States Mammalian Biologics CDMO Service Market
  • 7.5 Canadian Mammalian Biologics CDMO Service Market
  • 7.6 Mexican Mammalian Biologics CDMO Service Market

8. European Mammalian Biologics CDMO Service Market

  • 8.1 Overview
  • 8.2 European Mammalian Biologics CDMO Service Market by Type
  • 8.3 European Mammalian Biologics CDMO Service Market by Application
  • 8.4 German Mammalian Biologics CDMO Service Market
  • 8.5 French Mammalian Biologics CDMO Service Market
  • 8.6 Italian Mammalian Biologics CDMO Service Market
  • 8.7 Spanish Mammalian Biologics CDMO Service Market
  • 8.8 The United Kingdom Mammalian Biologics CDMO Service Market

9. APAC Mammalian Biologics CDMO Service Market

  • 9.1 Overview
  • 9.2 APAC Mammalian Biologics CDMO Service Market by Type
  • 9.3 APAC Mammalian Biologics CDMO Service Market by Application
  • 9.4 Chinese Mammalian Biologics CDMO Service Market
  • 9.5 Indian Mammalian Biologics CDMO Service Market
  • 9.6 Japanese Mammalian Biologics CDMO Service Market
  • 9.7 South Korean Mammalian Biologics CDMO Service Market
  • 9.8 Indonesian Mammalian Biologics CDMO Service Market

10. ROW Mammalian Biologics CDMO Service Market

  • 10.1 Overview
  • 10.2 ROW Mammalian Biologics CDMO Service Market by Type
  • 10.3 ROW Mammalian Biologics CDMO Service Market by Application
  • 10.4 Middle Eastern Mammalian Biologics CDMO Service Market
  • 10.5 South American Mammalian Biologics CDMO Service Market
  • 10.6 African Mammalian Biologics CDMO Service Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunity by Type
    • 12.2.2 Growth Opportunity by Application
  • 12.3 Emerging Trends in the Global Mammalian Biologics CDMO Service Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis Overview
  • 13.2 Lonza
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Catalent
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Samsung Biologics
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 FUJIFILM Diosynth Biotechnologies
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Boehringer Ingelheim
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 WuXi AppTech
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Recipharm
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.9 Thermo Fisher Scientific
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.10 AGC Biologics
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.11 Rentschler Biopharma
    • Company Overview
    • Mammalian Biologics CDMO Service Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us